US HHS buys more antivirals
US Health and Human Services Secretary Mike Leavitt has announced the purchase of additional antiviral drugs that could be used in the event of a potential influenza pandemic. The Department has ordered 1.75 million treatment courses of the antiviral drug Relenza (zanamivir) from UK-headquartered pharmaceuticals giant GlaxoSmithKline and 12.4 million treatment courses of Tamiflu (oseltamivir) from Switzerland-based drugs and diagnostics major Roche.
These drugs will be added to the already purchased 5.5 million treatment courses of antiviral drugs for the strategic national stockpile and be provided to US states when an influenza pandemic is deemed to be imminent.
"Having a stockpile of antiviral drugs is an important part of our pandemic influenza preparedness plan," Secretary Leavitt said, noting that "these purchases are a continuation of our aggressive multi-pronged approach to a potentially critical public health challenge."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze